Look back at pharma news in the week to August 27, 2021
By Barbara Obstoj-Cardwell
Among the notable news announced last week, US pharma giant Pfizer said it has reached agreement to acquire Canadian immune-oncology drug developer Trillium Therapeutics, in a deal that carries a price tag of $2.226 billion. Also of note, the US Food and Drug Administration granted full approval for Pfizer and BioNTech’s blockbuster COVID-19 vaccine Comirnaty. Danish biotech Ascendis Pharma gained FDA clearance to market its pediatric growth hormone deficiency drug Skytrofa. China’s Brii Biosciences announced Phase III clinical data on its COVID-19 antibody combination therapeutic – BRII-196/BRII-198. And BioMarin Pharmaceutical received European Commission approval for its Voxzogo (vosoritide) in the treatment of achondroplasia, a rare disease that is the most common cause of dwarfism.
Trillium gets a buyout while it’s down
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze